For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 3,766,915 | 3,677,230 | 4,667,133* | 3,739,948 |
| General & administrative | 1,559,094 | 1,691,576 | 3,675,954* | 1,748,935 |
| Total operating expenses | 5,326,009 | 5,368,806 | 8,343,087 | 5,488,883 |
| Operating loss | -5,326,009 | -5,368,806 | -8,343,087* | -5,488,883 |
| Interest expense, net | -117,485 | -87,789 | -132,794* | -172,050 |
| Other expense | -22,257 | -12,851 | 58,938* | -3,771 |
| Net loss | -5,465,751 | -5,469,446 | -8,416,943* | -5,664,704 |
| Modification of warrants | - | - | 0* | 0 |
| Net loss available to common shareholders | -5,465,751 | -5,469,446 | -8,416,943 | -5,664,704 |
| Diluted EPS | -0.67 | -0.68 | -2.125 | -1.36 |
| Diluted Average Shares | 8,138,233 | 8,015,739 | 3,960,774 | 4,150,702 |
CEL SCI CORP (CVM)
CEL SCI CORP (CVM)